Phibro Animal Health (NASDAQ:PAHC) Upgraded by StockNews.com to Strong-Buy Rating

Phibro Animal Health (NASDAQ:PAHC) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Several other research analysts have also weighed in on PAHC. JPMorgan Chase & Co. started coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 target price on the stock. Barclays raised their price objective on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Finally, Morgan Stanley lifted their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and an average target price of $20.50.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $20.52 on Friday. The company has a market cap of $831.12 million, a P/E ratio of 47.72, a P/E/G ratio of 0.58 and a beta of 0.51. The firm’s 50 day moving average is $23.01 and its two-hundred day moving average is $20.96. Phibro Animal Health has a fifty-two week low of $10.03 and a fifty-two week high of $25.98. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds have recently modified their holdings of the stock. Brandes Investment Partners LP lifted its position in shares of Phibro Animal Health by 1.2% during the second quarter. Brandes Investment Partners LP now owns 2,405,629 shares of the company’s stock worth $40,521,000 after purchasing an additional 29,071 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Phibro Animal Health by 5.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 775,470 shares of the company’s stock worth $13,005,000 after buying an additional 42,086 shares during the period. Acadian Asset Management LLC lifted its holdings in Phibro Animal Health by 6.3% in the 2nd quarter. Acadian Asset Management LLC now owns 717,506 shares of the company’s stock worth $12,027,000 after buying an additional 42,299 shares in the last quarter. Dana Investment Advisors Inc. boosted its position in Phibro Animal Health by 17.2% in the 2nd quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after buying an additional 75,546 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Phibro Animal Health by 5.7% during the third quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock valued at $11,430,000 after acquiring an additional 27,201 shares in the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.